Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-15T18:14:26.700Z Has data issue: false hasContentIssue false

Advancing pediatric antimicrobial stewardship: Has pharmacodynamic dosing for gram-negative infections taken effect?

Published online by Cambridge University Press:  10 December 2021

Lauren M. Puckett
Affiliation:
University of Connecticut School of Pharmacy Storrs, ConnecticutConnecticut Children’s, Hartford, Connecticut
Jason G. Newland
Affiliation:
Washington University School of Medicine, St Louis, MissouriAntimicrobial Stewardship Program, Saint Louis Children’s Hospital, St Louis, Missouri
Jennifer E. Girotto*
Affiliation:
University of Connecticut School of Pharmacy Storrs, ConnecticutConnecticut Children’s, Hartford, Connecticut
*
Author for correspondence: Jennifer E. Girotto, PharmD, BCPPS, BCIDP, University of Connecticut, School of Pharmacy, 69 North Eagleville Road, Storrs, CT 06269. E-mail: jennifer.girotto@uconn.edu

Abstract

Objective:

To characterize pharmacodynamic dosing strategies used at children’s hospitals using a national survey.

Design:

Survey.

Setting:

Children’s hospitals.

Participants:

Volunteer sample of antimicrobial stewardship program (ASP) respondents.

Methods:

A nationwide survey was conducted to gain greater insight into the current adoption of nontraditional dosing methods and monitoring of select β-lactam and fluoroquinolone antibiotics used to treat serious gram-negative infections in pediatric populations. The survey was performed through the Sharing Antimicrobial Reports for Pediatric Stewardship (SHARPS) Collaborative.

Results:

Of the 75 children’s hospitals that responded, 68% of programs reported adoption of pharmacodynamically optimized dosing using prolonged β-lactam infusions and 35% using continuous β-lactam infusions, although use was infrequent. Factors including routine MIC monitoring and formal postgraduate training and board certification of ASP pharmacists were associated with increased utilization of pharmacodynamic dosing. In addition, 60% of programs reported using pharmacodynamically optimized ciprofloxacin and 14% reported using pharmacodynamically optimized levofloxacin. Only 20% of programs monitored β-lactam levels; they commonly cited lack of published guidance, practitioner experience, and laboratomory support as reasons for lack of utilization. Less physician time dedicated to ASP programs was associated with lower adoption of optimized dosing.

Conclusions:

Use of pharmacodynamic dosing through prolonged and continuous infusions of β-lactams have not yet been routinely adopted at children’s hospitals. Further guidance from trials and literature are needed to continue to guide pediatric pharmacodynamic dosing efforts. Children’s hospitals should utilize these data to compare practices and to prioritize further research and education efforts.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction in any medium, provided the original article is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Dedicated Physician Full Time Equivalent to ASP Activities in Relation to Use of Pharmacodynamic Dose Modification

Figure 1

Table 2.Pharmacist Training in Relation to Modified Dosing Regimens Based on Patient Factors

Figure 2

Fig. 1.Relation of pharmacist training to frequency of use of prolonged infusions of β-lactams. Note. PGY, postgraduate year of training; BCPPS, board-certified pediatric pharmacy specialist; BCPS, board-certified pharmacotherapy specialist; BCIDP, board-certified infectious diseases pharmacist. (1) PGY1 or higher includes pharmacists that noted training of PGY1, PGY2 (any type), fellowship or any combination of those training modalities. (2) Pediatrics training includes pediatrics (PGY2 or fellowship). (3) Pharmacist infectious diseases training includes infectious disease (PGY2 or fellowship) and pediatric infectious disease (PGY2 or fellowship). (4) Pediatric infectious diseases training includes only pediatric infectious disease (PGY2 or fellowship). (5) Some pharmacists have multiple trainings, so numbers of specific trainings are higher than the overall number with board certification are higher than overall number with board certification.

Figure 3

Fig. 2.Relation of Pharmacist training to frequency of use of continuous infusions of β-lactams. Note. PGY, postgraduate year of training; BCPPS, board-certified pediatric pharmacy specialist; BCPS, board-certified pharmacotherapy specialist; BCIDP, board-certified infectious diseases pharmacist. (1) PGY1 or higher includes pharmacists that noted training of PGY1, PGY2 (any type), fellowship or any combination of those training modalities. (2) Pediatrics training includes pediatrics (PGY2 or fellowship). (3) Pharmacist infectious diseases training includes infectious disease (PGY2 or fellowship) and pediatric infectious disease (PGY2 or fellowship). (4) Pediatric infectious diseases training includes only pediatric infectious disease (PGY2 or fellowship). (5) Some pharmacists have multiple trainings, so numbers of specific trainings are higher than the overall number with board certification are higher than overall number with board certification.

Supplementary material: File

Puckett et al. supplementary material

Table S1

Download Puckett et al. supplementary material(File)
File 24.1 KB